» Articles » PMID: 22342985

Defining "epileptogenesis" and Identifying "antiepileptogenic Targets" in Animal Models of Acquired Temporal Lobe Epilepsy is Not As Simple As It Might Seem

Overview
Specialties Neurology
Pharmacology
Date 2012 Feb 21
PMID 22342985
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The "latent period" between brain injury and clinical epilepsy is widely regarded to be a seizure-free, pre-epileptic state during which a time-consuming cascade of molecular events and structural changes gradually mediates the process of "epileptogenesis." The concept of the "latent period" as the duration of "epileptogenesis" implies that epilepsy is not an immediate result of brain injury, and that anti-epileptogenic strategies need to target delayed secondary mechanisms that develop sometime after an initial injury. However, depth recordings made directly from the dentate granule cell layers in awake rats after convulsive status epilepticus-induced injury have now shown that whenever perforant pathway stimulation-induced status epilepticus produces extensive hilar neuron loss and entorhinal cortical injury, hyperexcitable granule cells immediately generate spontaneous epileptiform discharges and focal or generalized behavioral seizures. This indicates that hippocampal injury caused by convulsive status epilepticus is immediately epileptogenic and that hippocampal epileptogenesis requires no delayed secondary mechanism. When latent periods do exist after injury, we hypothesize that less extensive cell loss causes an extended period during which initially subclinical focal seizures gradually increase in duration to produce the first clinical seizure. Thus, the "latent period" is suggested to be a state of "epileptic maturation," rather than a prolonged period of "epileptogenesis," and therefore the antiepileptogenic therapeutic window may only remain open during the first week after injury, when some delayed cell death may still be preventable. Following the perhaps unavoidable development of the first focal seizures ("epileptogenesis"), the most fruitful therapeutic strategy may be to interrupt the process of "epileptic maturation," thereby keeping focal seizures focal. This article is part of the Special Issue entitled 'New Targets and Approaches to the Treatment of Epilepsy'.

Citing Articles

Targeting Adipokines: A Promising Therapeutic Strategy for Epilepsy.

Shaikh I, Bhatt L Neurochem Res. 2024; 49(11):2973-2987.

PMID: 39060767 DOI: 10.1007/s11064-024-04219-4.


Seizure-induced neutrophil adhesion in brain capillaries leads to a decrease in postictal cerebral blood flow.

Lim H, Bae S, Han K, Kang B, Jeong Y, Kim S iScience. 2023; 26(5):106655.

PMID: 37168551 PMC: 10164910. DOI: 10.1016/j.isci.2023.106655.


Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs.

Lukasiuk K, Lason W Int J Mol Sci. 2023; 24(3).

PMID: 36769250 PMC: 9917847. DOI: 10.3390/ijms24032928.


EEG biomarker candidates for the identification of epilepsy.

Gallotto S, Seeck M Clin Neurophysiol Pract. 2023; 8:32-41.

PMID: 36632368 PMC: 9826889. DOI: 10.1016/j.cnp.2022.11.004.


Normal and Abnormal Sharp Wave Ripples in the Hippocampal-Entorhinal Cortex System: Implications for Memory Consolidation, Alzheimer's Disease, and Temporal Lobe Epilepsy.

Zhen Z, Guo M, Li H, Guo O, Zhen J, Fu J Front Aging Neurosci. 2021; 13:683483.

PMID: 34262446 PMC: 8273653. DOI: 10.3389/fnagi.2021.683483.


References
1.
Van Paesschen W, Duncan J, Stevens J, Connelly A . Etiology and early prognosis of newly diagnosed partial seizures in adults: a quantitative hippocampal MRI study. Neurology. 1997; 49(3):753-7. DOI: 10.1212/wnl.49.3.753. View

2.
Giblin K, Blumenfeld H . Is epilepsy a preventable disorder? New evidence from animal models. Neuroscientist. 2010; 16(3):253-75. PMC: 2911489. DOI: 10.1177/1073858409354385. View

3.
Chang B, Lowenstein D . Epilepsy. N Engl J Med. 2003; 349(13):1257-66. DOI: 10.1056/NEJMra022308. View

4.
Langer M, Brandt C, Zellinger C, Loscher W . Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats. Neuropharmacology. 2011; 61(5-6):1033-47. DOI: 10.1016/j.neuropharm.2011.06.015. View

5.
Poirier J, capek R, De Koninck Y . Differential progression of Dark Neuron and Fluoro-Jade labelling in the rat hippocampus following pilocarpine-induced status epilepticus. Neuroscience. 2000; 97(1):59-68. DOI: 10.1016/s0306-4522(00)00026-9. View